Persistence of humoral immune response to SARS-CoV-2 up to 7 months post-infection: Cross-sectional study, South India, 2020–21

Thangaraj, Jeromie Wesley Vivian; Kumar, Muthusamy Santhosh; Kumar, Cp Girish; Kumar, Vivek; Kumar, Nathella Pavan; Bhatnagar, Tarun; Ponnaiah, Manickam; Sabarinathan, R.; D, Sudharani; Nancy, Arul; Jagadeesan, M; Babu, Subash; Murhekar, Manoj

doi:10.1016/j.jinf.2021.05.026

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like previous reports, there was no apparent correlation between the IgG level and the severity of COVID-19 ( 23 , 24 ), however it is in contrast to another reports that show the individuals who recovered from severe disease possessed higher levels of all types of antibodies tested, perhaps because severe patients have a much higher viral load, which may elicit a stronger humoral response than patients with mild or asymptomatic disease ( 25 – 27 ). It maybe because of the differences between study groups and also the various immune system reactions.…”

Section: Discussionsupporting

confidence: 61%

Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection

Jafari,

Asli,

Moghbeli

et al. 2023

IJM

View full text Add to dashboard Cite

Background and Objectives: Coronavirus disease 2019 (COVID-19) pandemic has affected most countries in the world. Monitoring the humoral immune responses during the natural course of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection and the duration of them provide useful information for the development of vaccination strategies against this virus and its emerging variants. The importance of the antibody response especially neutralizing antibodies in long-term immunity to SARS-CoV-2 is significant. Materials and Methods: The present study is a cross-sectional study of sero-epidemiological type that has been proposed to compare the persistence of Immunoglobulin G (IgG) against N (nucleocapsid), S (spike) and RBD (receptor-binding domain) proteins in the community after the time of primary disease. A total of 652 serum samples were collected from hospital staff working in COVID wards, as well as a number of community members with different occupations, among those with positive antibody titers, 86 participated in the resampling test before vaccination. Results: There was no association between antibody titer and disease severity (p>0.05). A significant decrease in Ab levels was observed in the paired second samples. The highest rate of decrease was related to anti-N, then anti-RBD and anti-S IgG levels, respectively. There is a significant relationship between the initial antibody titer and its reduction over time (p-value<0.05). Conclusion: Our data revealed that humoral immunity following natural infection of SARS-CoV-2 is detectable for at least 4 months, regardless of disease severity. The most decrease in antibody titer over time was related to anti-N IgG levels.

show abstract

Section: Discussionsupporting

confidence: 61%

Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection

Jafari,

Asli,

Moghbeli

et al. 2023

IJM

View full text Add to dashboard Cite

show abstract

“…While a fall in titer was seen for anti-nucleocapsid antibodies at 3 months, 94% of the individual with anti-spike antibodies maintained a detectable titer at 6 months, although a quantitative analysis was not done 25 . Also Thangaraj et al 30 observed a clear waning of anti-nucleocapside and anti-spike antibodies, but the persistence of neutralizing, anti-receptor binding domain antibodies in 86.2% of participants after more than 6 months from diagnosis and Epaulard et al 30 confirmed this finding with a longer follow-up. In their report, neutralizing, anti-receptor binding domain antibodies remain detectable 7 months after infection in 65 of 67 patients, and antibody levels remain stable between 6 months and 1 year.…”

Section: Discussionmentioning

confidence: 93%

Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection

Novello¹,

Terzolo²,

Berchialla³

et al. 2021

Sci Rep

View full text Add to dashboard Cite

It is partially unknown whether the immune response to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection persists with time. To address this issue, we detected the presence of SARS-CoV-2 antibodies in different groups of individuals previously diagnosed with COVID-19 disease (group 1 and 2), or potentially exposed to SARS-CoV-2 infection (group 3 and 4), and in a representative group of individuals with limited environmental exposure to the virus due to lockdown restrictions (group 5). The primary outcome was specific anti-SARS-CoV-2 antibodies in the different groups assessed by qualitative and quantitative analysis at baseline, 3 and 6 months follow-up. The seroconversion rate at baseline test was 95% in group 1, 61% in group 2, 40% in group 3, 17% in group 4 and 3% in group 5. Multivariate logistic regression analysis revealed male gender, close COVID-19 contact and presence of COVID-19 related symptoms strongly associated with serological positivity. The percentage of positive individuals as assessed by the qualitative and quantitative tests was superimposable. At the quantitative test, the median level of SARS-CoV-2 antibody levels measured in positive cases retested at 6-months increased significantly from baseline. The study indicates that assessing antibody response to SARS-CoV-2 through qualitative and quantitative testing is a reliable disease surveillance tool.

show abstract

Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2

Deshpande¹,

Kaduskar²,

Bhatt³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Persistence of humoral immune response to SARS-CoV-2 up to 7 months post-infection: Cross-sectional study, South India, 2020–21

Cited by 5 publications

References 20 publications

Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection

Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection

Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection

Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2

Contact Info

Product

Resources

About